Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
NLS Pharmaceutics ( (NLSP) ) has issued an update.
On January 30, 2025, NLS Pharmaceutics announced the submission of three research abstracts to the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP). These abstracts explore innovative therapies for managing fentanyl addiction, narcolepsy, and diabetes-related neurological disorders, reflecting the company’s commitment to advancing neuropsychopharmacology. This move positions NLS Pharmaceutics as a key contributor to cutting-edge research in their field, potentially strengthening their market position and impact on stakeholders.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders. The company collaborates with renowned scientists and pharmaceutical partners to address unmet medical needs in areas such as addiction medicine, sleep disorders, and cognitive dysfunction.
YTD Price Performance: -10.09%
Average Trading Volume: 1,198,556
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.65M
See more insights into NLSP stock on TipRanks’ Stock Analysis page.
